Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ N-sulfated Heparan Sulfate Monoclonal Antibody (HepSS-1), Biotin

Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA546186
This item is not returnable.
View return policy
Description
This antibody recognizes N-sulfated heparan sulfate (extracellular antigen) present in many species.
Heparan sulfate (HS) is a glycosaminoglycan that is ubiquitously expressed on cell surfaces and in the extracellular matrix and basement membrane. Each HS molecule is a linear polysaccharide composed of repeating disaccharides of hexuronic acid and d-glucosamine that can exhibit immense structural diversity due to substitution to varying extents with sulfate groups and epimerization of glucuronic acid to iduronic acid, with areas of high sulfation and glucuronic acid epimerization being co-located in hot spots throughout the molecule. HS is structurally related to heparin, an extremely highly sulfated form of HS that is restricted to mast cells. The biosynthesis and modification of HS chains is thought to take place within the endoplasmic reticulum, Golgi apparatus, and trans Golgi network, which in the end produce unique HS chains that are covalently attached to a range of core proteins to form HS-proteoglycans [PMID: 24391644].
Specifications
N-sulfated Heparan Sulfate | |
Monoclonal | |
1 mg/mL | |
TBS with 15mM sodium azide; pH 8 | |
Mouse | |
Size-exclusion chromatography | |
RUO | |
Chemical | |
Antibody | |
IgM |
Flow Cytometry, Immunohistochemistry, Immunoprecipitation, Western Blot, Immunocytochemistry | |
HepSS-1 | |
Biotin | |
Heparan sulfate | |
MethA murine fibrosarcoma. | |
100 μg | |
Primary | |
4°C, do not freeze | |
Liquid | |
Chemical |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction